progenics Message Board - Msg: 25104468

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : progenics

PGNX 4.100

-9.4%

Jun 19 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tom pope who wrote (122)	10/24/2008 11:48:27 AM
From: tuck	Read Replies (1) of 139

I had cashed out of my sold puts a while back, but I bought a little stock today in the $8.50s. Relistor is off to a slower start than I expected, apparently because Wyeth was a bit gunshy about making marketing expenditures before approval, when approval was not a given. Rumor has it this has been corrected. See this post concerning the WYE cc: messages.finance.yahoo.com I gather there is data on PRO140 coming tomorrow. I would guess the data will be good, and should help the stock going forward, with the caveat that even a good HIV drug is going to be tough commercial sledding if it's injection only. I remember the Lucentis launch, where DNA actually booked 10 million in sales the day after it was approved! With the FDA having gone from cautious mode to ultra-cautious mode, drug companies may also be cautious about committing to a fast start, since that would be wasted money if the FDA punts or gives the thumbs down. Going forward this means, buying pullbacks after approvals -- rather than trying to anticipate them -- is probably the best strategy. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next